Literature DB >> 8920822

Lactoferrin-mediated protection of the host from murine cytomegalovirus infection by a T-cell-dependent augmentation of natural killer cell activity.

K Shimizu1, H Matsuzawa, K Okada, S Tazume, S Dosako, Y Kawasaki, K Hashimoto, Y Koga.   

Abstract

The administration of bovine lactoferrin (LF) with 1 mg/g body weight before the murine cytomegalovirus (MCMV) infection completely protected the BALB/c mice from death due to the infection. In these LF-treated mice, a significant increase in the activity was found in the NK cells but not in the cytolytic T lymphocytes which recognized an MCMV-derived peptide. Moreover, the elimination of the NK cell activity by an injection with anti-asialo GM1 antibody abrogated such augmented resistance, thus supporting the hypothesis that the LF-mediated antiviral effect in vivo is performed through the augmentation of NK cell activity. No such LF-mediated antiviral effect in vivo with the increased NK cell activity was found in athymic nude mice, whereas it was restored completely by the transfer of splenic T cells from LF-treated donors. These findings therefore suggest that T lymphocytes induce both the augmentation of NK cell activity and the resultant antiviral effect in the LF-treated hosts.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8920822     DOI: 10.1007/bf01718201

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  28 in total

Review 1.  Cellular and molecular basis of the protective immune response to cytomegalovirus infection.

Authors:  U H Koszinowski; M Del Val; M J Reddehase
Journal:  Curr Top Microbiol Immunol       Date:  1990       Impact factor: 4.291

2.  Cytotoxic T lymphocyte response to murine cytomegalovirus infection.

Authors:  G V Quinnan; J E Manischewitz; F A Ennis
Journal:  Nature       Date:  1978-06-15       Impact factor: 49.962

3.  A pentapeptide as minimal antigenic determinant for MHC class I-restricted T lymphocytes.

Authors:  M J Reddehase; J B Rothbard; U H Koszinowski
Journal:  Nature       Date:  1989-02-16       Impact factor: 49.962

4.  Lactoferrin decreases monocyte-induced fibroblast production of myeloid colony-stimulating activity by suppressing monocyte release of interleukin-1.

Authors:  J R Zucali; H E Broxmeyer; D Levy; C Morse
Journal:  Blood       Date:  1989-10       Impact factor: 22.113

5.  Fate of human lactoferrin and myeloperoxidase in phagocytizing human neutrophils: effects of immunoglobulin G subclasses and immune complexes coated on latex beads.

Authors:  M S Leffell; J K Spitznagel
Journal:  Infect Immun       Date:  1975-10       Impact factor: 3.441

6.  Modification of susceptibility to Klebsiella pneumoniae during murine cytomegalovirus infection.

Authors:  W C Leung; K Hashimoto
Journal:  Microbiol Immunol       Date:  1986       Impact factor: 1.955

7.  Modulation of natural killer and lymphokine-activated killer cell cytotoxicity by lactoferrin.

Authors:  H Shau; A Kim; S H Golub
Journal:  J Leukoc Biol       Date:  1992-04       Impact factor: 4.962

8.  In vivo effects of anti-asialo GM1. I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice.

Authors:  S Habu; H Fukui; K Shimamura; M Kasai; Y Nagai; K Okumura; N Tamaoki
Journal:  J Immunol       Date:  1981-07       Impact factor: 5.422

9.  Iron is not required in the lactoferrin stimulation of thymidine incorporation into the DNA of rat crypt enterocytes.

Authors:  B L Nichols; K S McKee; H A Huebers
Journal:  Pediatr Res       Date:  1990-05       Impact factor: 3.756

10.  Genetic influences on the augmentation of natural killer (NK) cells during murine cytomegalovirus infection: correlation with patterns of resistance.

Authors:  G J Bancroft; G R Shellam; J E Chalmer
Journal:  J Immunol       Date:  1981-03       Impact factor: 5.422

View more
  13 in total

1.  CHO expressed recombinant human lactoferrin as an adjuvant for BCG.

Authors:  Shen-An Hwang; Marian L Kruzel; Jeffrey K Actor
Journal:  Int J Immunopathol Pharmacol       Date:  2015-08-27       Impact factor: 3.219

2.  The antiviral protein human lactoferrin is distributed in the body to cytomegalovirus (CMV) infection-prone cells and tissues.

Authors:  Leonie Beljaars; Hester I Bakker; Barry W A van der Strate; Catharina Smit; Adrian M Duijvestijn; Dirk K F Meijer; Grietje Molema
Journal:  Pharm Res       Date:  2002-01       Impact factor: 4.200

3.  Viral load in breast milk correlates with transmission of human cytomegalovirus to preterm neonates, but lactoferrin concentrations do not.

Authors:  B W van der Strate; M C Harmsen; P Schäfer; P J Swart; T H The; G Jahn; C P Speer; D K Meijer; K Hamprecht
Journal:  Clin Diagn Lab Immunol       Date:  2001-07

4.  A cytotoxic effect of human lactoferrin fusion with Fc domain of IgG.

Authors:  Ewa Zaczyńska; Maja Kocięba; Jolanta Artym; Iwona Kochanowska; Marian L Kruzel; Michał Zimecki
Journal:  Biometals       Date:  2022-09-22       Impact factor: 3.378

5.  Inhibition of HBV infection by bovine lactoferrin and iron-, zinc-saturated lactoferrin.

Authors:  Songtao Li; Haibo Zhou; Guirong Huang; Ning Liu
Journal:  Med Microbiol Immunol       Date:  2008-09-23       Impact factor: 3.402

Review 6.  Impact of breast milk-acquired cytomegalovirus infection in premature infants: Pathogenesis, prevention, and clinical consequences?

Authors:  Erin A Osterholm; Mark R Schleiss
Journal:  Rev Med Virol       Date:  2020-07-13       Impact factor: 11.043

Review 7.  Lactoferrin, a unique molecule with diverse therapeutical and nanotechnological applications.

Authors:  Sally Sabra; Mona M Agwa
Journal:  Int J Biol Macromol       Date:  2020-07-22       Impact factor: 6.953

Review 8.  Antiviral properties of lactoferrin--a natural immunity molecule.

Authors:  Francesca Berlutti; Fabrizio Pantanella; Tiziana Natalizi; Alessandra Frioni; Rosalba Paesano; Antonella Polimeni; Piera Valenti
Journal:  Molecules       Date:  2011-08-16       Impact factor: 4.411

Review 9.  Early inhibitors of human cytomegalovirus: state-of-art and therapeutic perspectives.

Authors:  Beatrice Mercorelli; David Lembo; Giorgio Palù; Arianna Loregian
Journal:  Pharmacol Ther       Date:  2011-04-28       Impact factor: 12.310

Review 10.  Current scenario of peptide-based drugs: the key roles of cationic antitumor and antiviral peptides.

Authors:  Kelly C L Mulder; Loiane A Lima; Vivian J Miranda; Simoni C Dias; Octávio L Franco
Journal:  Front Microbiol       Date:  2013-10-31       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.